Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Watson Says Received Favorable Ruling Over Generic Sanctura XR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/04/2012 | 12:19am CEST

Watson Pharmaceuticals Inc. (>> Watson Pharmaceuticals, Inc.) said it received a favorable court ruling over a patent dispute with Allergan Inc. (AGN) and its business partners regarding Watson's plans for a generic version of an overactive bladder medication.

Allergan and its partners in 2009 sued Watson and its business partners, alleging infringement of patents related to Allergan's Sanctura XR drug.

Watson said Tuesday a U.S. District Court in Delaware found several Sanctura XR patents invalid, benefiting Watson and allowing it to potentially move forward with its abbreviated new drug application for generic version of the drug, which is pending with the Food and Drug Administration.

An Allergan representative wasn't immediately available for comment.

Watson has seen strong sales of its generics as health-care companies and consumers try to reduce spending on health-related products and services. Watson is trying to expand its brand-name drug business, though it recently hit a regulatory setback with a proposed new drug to prevent premature births.

The company benefited from its introduction of authorized generic versions of Johnson & Johnson's (JNJ) Concerta treatment for attention-deficit/hyperactivity disorder in May, as well as Pfizer's (PFE) Lipitor cholesterol-lowering drug in November.

Watson in February said its fourth-quarter profit surged as the introduction of generic Lipitor and other products boosted sales.

Watson's shares closed Tuesday at $66.96 and were down 6 cents after hours. Allergan's shares closed at $95.27 and were off 10 cents after hours.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; [email protected]

Stocks mentioned in the article : Watson Pharmaceuticals, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACTAVIS INC
06/27 ALLERGAN : Introduces REFRESH OPTIVE® MEGA-3 Enhanced with Flaxseed Oil, Latest ..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/20 Inhalation & Nasal Spray Generic Drugs Market - Global Trends, Market Share, ..
06/15 ALLERGAN : to Present New Data on Chronic Migraine at the American Headache Soci..
06/15 AMGEN : And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, ..
06/15 ALLERGAN : to Acquire Keller Medical, Inc., Adding Keller Funnel® to Company's L..
06/14 BIOTIME : Renevia succeeds in pivotal European facial wasting trial
06/09 ALLERGAN : to Present at the Goldman Sachs Global Healthcare Conference
06/09 ALLERGAN : to Present Data from its Anti-Infectives Portfolio at ASM Microbe 201..
More news
Sector news : Pharmaceuticals - NEC
06/27DJMERCK AND : Says Its Network Was Hit by Global Hack
06/26DJASTRAZENECA : ADRs End Mostly Higher
06/26 VALEANT PHARMACEUTICALS INTL : Hedge fund Paulson & Co discloses 6.3 percent sta..
06/26DJHow Third Point's Nestlé Move Could Affect L'Oréal
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
More sector news : Pharmaceuticals - NEC
Advertisement
Financials ($)
Sales 2017 15 806 M
EBIT 2017 7 607 M
Net income 2017 -1 759 M
Debt 2017 16 935 M
Yield 2017 1,17%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 6,30x
EV / Sales 2018 5,86x
Capitalization 82 654 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 270 $
Spread / Average Target 9,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACTAVIS INC82 778
JOHNSON & JOHNSON18.34%367 520
NOVARTIS12.55%225 386
ROCHE HOLDING LTD.8.21%224 497
PFIZER3.97%203 487
MERCK AND COMPANY11.33%180 958
More Results